<DOC>
	<DOCNO>NCT00002827</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Radiation therapy use high-energy x-rays damage cancer cell . Combining chemotherapy radiation therapy may kill cancer cell . It yet know chemotherapy effective without dexrazoxane Hodgkin 's disease . PURPOSE : Randomized phase III trial compare effectiveness combination chemotherapy , without dexrazoxane , follow radiation therapy treat young patient newly diagnose stage I , stage II , stage III Hodgkin 's disease .</brief_summary>
	<brief_title>Chemotherapy Followed Radiation Therapy Treating Young Patients With Newly Diagnosed Hodgkin 's Disease</brief_title>
	<detailed_description>OBJECTIVES : I . Modify chemotherapy course base initial response therapy child newly diagnose stage IA/IIA/IIIA1 Hodgkin 's disease . II . Examine activity variable course doxorubicin , bleomycin , vincristine , etoposide ( DBVE ) follow low-dose involved-field irradiation patient . III . Monitor safety feasibility response-dependent approach morbidity immediate long-term toxic effect associate regimen . IV . Assess whether limited therapy adequate patient early response . V. Evaluate whether addition dexrazoxane reduce pulmonary toxicity significantly reduce response rate event-free survival . VI . Evaluate whether frequency magnitude myocardial injury therapy , measure elevate serum cardiac troponin-T , reduce addition dexrazoxane . OUTLINE : This randomize study . Patients stratify participate institution . Patients randomly assign receive doxorubicin , bleomycin , vincristine , etoposide , filgrastim vs. without dexrazoxane . Filgrastim SC begin day 6-13 ; filgrastim give day 14 15 . Filgrastim restart 2 day complete therapy continue count recovery expect nadir ( ANC great 1000 cubic meter nadir ) . Courses repeat every 28 day . Those stable respond disease 2-4 course receive involved-field radiotherapy 5 day per week 3.5 week . Tanner stage IV/V patient eligible randomization base front-end institutional agreement may receive standard-field radiotherapy 5 day per week 11 week investigator 's discretion . Patients follow yearly relapse , death , minimum 10 year . PROJECTED ACCRUAL : A total 285 patient accrue study 5 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Cardiotoxicity</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Bleomycin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Dexrazoxane</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Razoxane</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically prove Hodgkin 's disease No 5 week since diagnostic biopsy No B symptoms Clinical/pathologic stage ( histology ) follow : Stage IA/IIA mediastinal mass le one third chest diameter Stage IIIA limit spleen splenic , celiac , portal node lesion large 6 cm Surgical staging require : Clinical imaging finding equivocal Tanner stage IV/V radiotherapy plan Concurrent registration protocol POG8828 ( late effect study ) POG 8829 ( epidemiology study ) require PATIENT CHARACTERISTICS : Age : 21 Performance status : Not specify Hematopoietic : No hematopoietic disease Hepatic : No liver disease Renal : No renal disease Other : No severe organ system damage failure No pregnant nursing woman PRIOR CONCURRENT THERAPY : No prior therapy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>stage II childhood Hodgkin lymphoma</keyword>
	<keyword>stage I childhood Hodgkin lymphoma</keyword>
	<keyword>stage III childhood Hodgkin lymphoma</keyword>
	<keyword>cardiac toxicity</keyword>
</DOC>